Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHI Premarin Results Support Short-Term Use; Breast Cancer Reduction May Be Bright Spot

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from the estrogen-only arm of Women's Health Initiative show increased risk of stroke, no effect on heart disease, and a trend towards reduced breast cancer. NIH says the results parallel current clinical recommendations that hormone therapy be used at the lowest dose for the shortest period of time.
Advertisement

Related Content

Wyeth Launches Prempro DTC Campaign Touting Lowest Treatment Dose
Wyeth Launches Prempro DTC Campaign Touting Lowest Treatment Dose
Wyeth Premarin Memory Data Are Mixed On Dementia Risk; 91% Of Rxs For Vasomotor Relief
Wyeth Premarin Memory Data Are Mixed On Dementia Risk; 91% Of Rxs For Vasomotor Relief
Wyeth Projects Prevnar Sales Of 20 Mil. Doses For 2004; Fill/Finish Facility Approved
Wyeth Projects Prevnar Sales Of 20 Mil. Doses For 2004; Fill/Finish Facility Approved
Premarin WHI Results May Mean Additional Label Changes, FDA Says
Premarin WHI Results May Mean Additional Label Changes, FDA Says
Hormone Therapy Labeling Should Include "Black Box" Warning On Dementia Risk, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS059101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel